EMA Authorised: Dimethyl fumarate Neuraxpharm (dimethyl fumarate) — Neuraxpharm Pharmaceuticals S.L.

View source ↗

Summary

The European Medicines Agency authorised Dimethyl fumarate from Neuraxpharm Pharmaceuticals S.L. for the treatment of multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Dimethyl fumarate Neuraxpharm (dimethyl fumarate)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Neuraxpharm Pharmaceuticals S.L.. Decision date: 12/02/2025